Eurofins Cerep SAS (ALECR) | Financial Analysis & Statements
Eurofins Cerep SAS Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
84.6M
Total Liabilities
11.0M
Shareholders Equity
73.5M
Debt to Equity
0.15
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Eurofins Cerep SAS Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 40.5M | 44.1M | 47.6M | 41.6M | 32.7M |
| Cost of Goods Sold | 23.0M | 23.9M | 24.0M | 20.8M | 16.8M |
| Gross Profit | 17.5M | 20.2M | 23.6M | 20.8M | 15.8M |
| Gross Margin % | 43.1% | 45.9% | 49.6% | 50.0% | 48.5% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | - | - |
| Other Operating Expenses | 919.6K | 1.7M | 1.6M | 1.4M | 3.3M |
| Total Operating Expenses | 919.6K | 1.7M | 1.6M | 1.4M | 3.3M |
| Operating Income | 4.7M | 6.4M | 11.7M | 10.1M | 5.6M |
| Operating Margin % | 11.6% | 14.6% | 24.6% | 24.3% | 17.3% |
| Non-Operating Items | |||||
| Interest Income | 292.2K | 278.5K | 14.9K | 0 | 2.5K |
| Interest Expense | 0 | 7.8K | 3.2K | 34.5K | 16.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 6.5M | 7.1M | 11.1M | 9.4M | 5.1M |
| Income Tax | -676.1K | -516.3K | -420.5K | -482.6K | -431.4K |
| Effective Tax Rate % | -10.4% | -7.2% | -3.8% | -5.2% | -8.4% |
| Net Income | 7.2M | 7.6M | 11.5M | 9.8M | 5.6M |
| Net Margin % | 17.7% | 17.3% | 24.2% | 23.7% | 17.1% |
| Key Metrics | |||||
| EBITDA | 8.6M | 9.2M | 12.9M | 10.9M | 6.5M |
| EPS (Basic) | €1,418.41 | €1,514.43 | €2,284.78 | €1,951.38 | €1,105.73 |
| EPS (Diluted) | €1,418.41 | €1,514.43 | €2,284.78 | €1,951.38 | €1,105.73 |
| Basic Shares Outstanding | 5044 | 5044 | 5044 | 5044 | 5044 |
| Diluted Shares Outstanding | 5044 | 5044 | 5044 | 5044 | 5044 |
Income Statement Trend
Eurofins Cerep SAS Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 17.6M | 8.6M | 12.8M | 1.3M | 4.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 7.9M | 9.1M | 8.2M | 7.1M | 5.9M |
| Inventory | 3.4M | 3.8M | 4.1M | 2.8M | 1.9M |
| Other Current Assets | -1 | - | - | - | - |
| Total Current Assets | 72.7M | 66.3M | 58.5M | 48.3M | 37.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 24.1M | 6.1M | 7.3M | 5.4M | 5.3M |
| Goodwill | 4.7M | 4.5M | 4.5M | 4.5M | 4.5M |
| Intangible Assets | 202.3K | 410 | 410 | 410 | 410 |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 63.8K | 153.7K | 320.3K | 102.4K | 324.7K |
| Total Non-Current Assets | 11.4M | 13.0M | 12.5M | 11.4M | 8.5M |
| Total Assets | 84.1M | 79.2M | 71.0M | 59.7M | 46.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.3M | 3.5M | 4.6M | 4.5M | 3.3M |
| Short-term Debt | 328.5K | 3.4K | 4.8K | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.6M | 2.7M | 3.0M | 527.5K | 403.4K |
| Total Current Liabilities | 10.5M | 12.8M | 12.3M | 11.7M | 8.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 0 | 0 | 18.9K | 20.0K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 146.4K | 48.1K | 138.0K | 635.6K | 635.6K |
| Total Non-Current Liabilities | 1.9M | 1.8M | 1.8M | 2.7M | 2.9M |
| Total Liabilities | 12.3M | 14.6M | 14.1M | 14.4M | 10.9M |
| Equity | |||||
| Common Stock | 75.7K | 75.7K | 75.7K | 75.7K | 75.7K |
| Retained Earnings | 50.7M | 43.5M | 35.9M | 24.4M | 20.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 71.7M | 64.6M | 56.9M | 45.4M | 35.1M |
| Key Metrics | |||||
| Total Debt | 328.5K | 3.4K | 4.8K | 18.9K | 20.0K |
| Working Capital | 62.2M | 53.5M | 46.2M | 36.6M | 29.6M |
Balance Sheet Composition
Eurofins Cerep SAS Cash Flow Statement
No cash flow data available.
Eurofins Cerep SAS Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.94
Price to Sales
2.05
Profitability Ratios
Profit Margin
15.86%
Operating Margin
5.70%
Return on Equity
8.74%
Return on Assets
2.92%
Financial Health
Current Ratio
8.28
Debt to Equity
0.10
Beta
0.02
Per Share Data
EPS (TTM)
€1,221.34
Revenue per Share
€8,020.87
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALECR | 79.7M | 12.94 | - | 8.74% | 15.86% | 0.10 |
| Eurofins Scientific | 10.8B | 24.24 | 3.08 | 9.50% | 6.51% | 96.84 |
| bioMérieux S.A | 8.4B | 21.24 | 2.04 | 9.54% | 9.77% | 11.24 |
| Klea Holding | 54.0M | 17.58 | 1.98 | 9.14% | 11.89% | 18.40 |
| Predilife S.A | 12.2M | - | - | -4,653.75% | 97.76% | -1.15 |
| Lumibird S.A | 540.6M | 38.59 | 2.64 | 6.93% | 6.13% | 70.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.